Bridgefront Capital, LLC Cytokinetics Inc Transaction History
Bridgefront Capital, LLC
- $129 Million
- Q1 2024
A detailed history of Bridgefront Capital, LLC transactions in Cytokinetics Inc stock. As of the latest transaction made, Bridgefront Capital, LLC holds 5,691 shares of CYTK stock, worth $312,094. This represents 0.31% of its overall portfolio holdings.
Number of Shares
5,691Holding current value
$312,094% of portfolio
0.31%Shares
1 transactions
Others Institutions Holding CYTK
# of Institutions
459Shares Held
108MCall Options Held
7.2MPut Options Held
6.2M-
Black Rock Inc. New York, NY12.4MShares$681 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$548 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.12MShares$281 Million0.22% of portfolio
-
Bank Of America Corp Charlotte, NC4.78MShares$262 Million0.03% of portfolio
-
State Street Corp Boston, MA4.52MShares$248 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $5.16B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...